Howard Chipman, MD
Family Medicine · Oldsmar, FLNPI 1417956293
Payments from drug & device makers
Across 372 payments — averaging $5023.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$611K
- Teva Pharmaceuticals USA, Inc.$489K
- Eli Lilly$341K
- Pfizer$80K
- Regeneron$75K
- CSL Behring$47K
- plus $225K from 23 others
Across 1 payment — averaging $951.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$951
What the payments were for
- Consulting fees$79,94498%
- Travel & lodging$8081%
- Food & beverage$8101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 87 | $611,389 |
| Teva Pharmaceuticals USA, Inc. | 64 | $489,235 |
| Eli Lilly | 8 | $341,118 |
| Pfizer | 13 | $80,028 |
| Regeneron | 36 | $75,248 |
| CSL Behring | 42 | $46,892 |
| Chiesi USA, Inc. | 10 | $43,754 |
| Braintree Laboratories, Inc. | 16 | $38,374 |
| Biogen | 1 | $38,023 |
| CSL Plasma Inc. | 42 | $33,052 |
| Boehringer Ingelheim | 2 | $17,792 |
| Adamis Pharmaceuticals Corporation | 9 | $14,857 |
| AstraZeneca | 2 | $9,617 |
| Orasure Technologies Inc. | 5 | $8,530 |
| Ionis Pharmaceuticals, Inc. | 4 | $8,300 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| Amgen | 1 | $4,375 |
| Boehringer Ingelheim International GmbH | 10 | $814 |
| Novo Nordisk | 7 | $220 |
| Boston Scientific | 1 | $57 |
| Lilly USA, LLC | 2 | $53 |
| Exact Sciences | 2 | $43 |
| Photonicare Inc | 1 | $27 |
| Abbott | 1 | $23 |
| Si-bone, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $17 |
| Indivior Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$121
How this compares
$1,868,578 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 18 | $20,593 |
| EliquisApixaban | 11 | $17,895 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $6,887 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $4,569 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 74 | $1,257 |
| Trazodone Hcl | 21 | $1,083 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $911 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $667 |
| Buprenorphine Hcl | 18 | $633 |
| Alprazolam | 77 | $517 |
| Gabapentin | 18 | $413 |
| Celecoxib | 12 | $393 |
| Levothyroxine Sodium | 37 | $329 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $316 |
| Lisinopril | 60 | $276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $53 | $20,59318 claims |
| PfizerEliquis | $80,028 | $17,89511 claims |
| Indivior Inc.Suboxone | $17 | $6,88711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Oldsmar
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.